Connect with us


Analysis Reveals That Clinical Trials Frequently Ignore Type 2 Diabetes



In spite of the fact that 37.3 million people in the United States have Type 2 Diabetes, which accounts for more than 11% of the population, only 365,000 people participated in a clinical trial in 2021, according to a new analysis of official records from the National Institutes of Health (NIH).

By participating in a clinical trial, individuals with conditions like diabetes can gain access to cutting-edge new medications and treatments, accelerate their introduction to the market, and benefit millions more.

The new findings were discovered by Lindus Health, a start-up company that conducts clinical trials. After conducting an analysis of the official records of clinical trials for a variety of diseases, Lindus Health discovered that diabetes was unquestionably underrepresented, with less than one percent of people who are affected by the disease participating in a trial.

Despite the fact that diabetes affects a large number of people, clinical trials frequently overlook the condition. This is notwithstanding the outcome of semaglutide as a treatment for diabetes and the developing market for successful treatments.

In 2021, the number of people living with cancer who took part in clinical trials was approximately 34% of the total. Similarly, in the same year, a trial for Alzheimer’s disease included approximately 7% of Alzheimer’s patients in the United States.

For those with chronic conditions, new treatments and care must be found through clinical trials. Diabetes sufferers run the risk of serious health issues if they do not receive the appropriate support. Diabetes is the seventh leading cause for death in the US, with the absolute assessed cost of analyzed diabetes in the US remaining at $327 billion.

In this context, Lindus Health is delivering clinical trials for treatments for Type 2 Diabetes three times faster than the industry standard, assisting in the quicker delivery of those treatments to patients.

One such study is a digital Type 2 Diabetes remission trial with the Habitual Remission Programme, which expects to find in the event that the Total Diet Replacement plan is bound to cause the inversion of type 2 diabetes contrasted with standard NHS care.

The trial, which was conducted entirely remotely, allows participants to enter their measurements and blood samples, as well as their data, from the comfort of their own homes. This helps to improve patient experiences and leads to better data.

Additionally, Lindus Health has conducted two pre-diabetes trials in the past: one with the digital therapeutics company dnaNudge and another with the gut-focused health technology start-up Myota.

The first trial looked at whether people with pre-diabetes could benefit from a DNA-based diet to lower their risk of developing type 2 diabetes. The second trial was designed to support an EFSA health claim for Myota’s fiber product.

What’s more, this year, Lindus Health is launching a trial aimed at treating and switching Type 2 Diabetes with George Medications.


error: Content is protected !!